Notably, across all 7 databases, patients in 5 datasets with high expression of PRDX5 were more likely to reach BCR, indicating that PRDX5 is the most promising biomarker within the PRDX family associated with BCR in prostate cancer. The gene discussed is BCR; the disease is prostate cancer.